| SKU | ISG008256 |
| Brand | Paroxedep |
| Categories | Medication & Treatments |
| Color | black |
| Concentrations | 37.5 Mg |
| Shop by Concerns | Anxiety Disorder |
| Gender | Unisex |
| Shop By Goals | Anxiety Relief |
| Imported Or Local | Local |
| Ingredient | Paroxetine |
| UPC | 6223003206260 |
| Product Form | Tablets |
| Specialty | Clinically Tested Controlled Release Prescription only |
| Sub Categories | Anti Depressants |
| Unit Count | 30 Tablets |
| Warning | Avoid alcohol and use caution when driving or operating machinery Do not touch any surface with dropper tip Do not use with MAOIs or within 14 days of stopping an MAOI May increase suicidal thoughts in young adults at treatment start Risk of serotonin syndrome Use With Caution With Anticoagulants |
Paroxedep Cr 37.5 Mg 30 Tablets
Description:
Paroxedep Cr 37.5 mg 30 tablets is a prescription antidepressant medicine containing paroxetine, a selective serotonin reuptake inhibitor (SSRI). It is formulated as controlled-release (CR) film-coated tablets to provide gradual release of the active ingredient over the day, helping to stabilize mood and reduce symptoms of depression and anxiety disorders. Manufactured by Apex Pharma, this medication is used under medical supervision to manage major depressive disorder, panic attacks, obsessive-compulsive disorder (OCD), and social anxiety disorder in adults. Always use Paroxedep Cr exactly as prescribed by your healthcare provider.
Indications:
- Treatment of major depressive disorder (MDD), including persistent low mood, loss of interest, fatigue, and sleep/appetite disturbances.
- Management of obsessive-compulsive disorder (OCD), helping to reduce recurrent intrusive thoughts and repetitive behaviors.
- Treatment of panic disorder, with or without agoraphobia, helping to reduce frequency and intensity of panic attacks.
- Management of social anxiety disorder (social phobia), reducing fear and avoidance of social or performance situations.
- May be used for other anxiety-related conditions as directed by a physician.
Active Ingredients / Key Components:
- Paroxetine (as paroxetine hydrochloride) – 37.5 mg per controlled-release film-coated tablet.
- Excipients: controlled-release matrix agents, film-coating materials, and standard tablet excipients (exact excipient list and concentrations , please check the product leaflet or the manufacturer’s official website; refer to the package insert for full details).
Dosage & Administration / How to Use:
- Use only as prescribed by a psychiatrist or qualified physician. Do not self-medicate with antidepressants.
- Typical adult dose: One controlled-release tablet once daily; the exact dose, including any titration up or down, is determined individually by the doctor based on condition and response.
- Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this will affect the controlled-release profile.
- Can usually be taken with or without food; taking it with food may help reduce gastrointestinal side effects.
- Take at the same time each day, preferably in the morning, unless your doctor advises otherwise.
- If you miss a dose, take it as soon as you remember on the same day. If it is almost time for the next dose, skip the missed dose and continue your regular schedule. Do not double the dose.
- Treatment duration is long term and may extend for several months or longer. Do not stop taking Paroxedep Cr suddenly without medical advice, as this may cause withdrawal symptoms. Your doctor will usually reduce the dose gradually when discontinuing.
- Regular follow-up with your doctor is essential to monitor response, side effects, and any dose adjustments.
Clinical Benefits:
- Helps restore the balance of serotonin in the brain, improving mood and emotional stability in patients with depression.
- Reduces frequency and severity of panic attacks and associated physical symptoms such as palpitations, sweating, and shortness of breath.
- Decreases obsessive thoughts and compulsive behaviors in OCD, improving daily functioning and quality of life.
- Alleviates excessive fear and avoidance in social anxiety disorder, supporting better social interaction and performance.
- Controlled-release formulation provides a more stable blood level of paroxetine over the day, which may improve tolerability and reduce peak-related side effects.
Warnings & Contraindications:
- Contraindicated in patients with known hypersensitivity to paroxetine or any component of the formulation.
- Do not use concomitantly with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI. Similarly, do not start an MAOI within 14 days of stopping paroxetine due to risk of serious, sometimes fatal reactions (including serotonin syndrome).
- Use with caution in patients taking warfarin or other anticoagulants, as paroxetine may increase bleeding risk. Close monitoring of coagulation parameters is recommended.
- Use with caution with other drugs affecting hepatic metabolism (enzyme inducers or inhibitors), as they may alter paroxetine blood levels.
- Increased risk of serotonin syndrome when combined with other serotonergic drugs (e.g., other SSRIs, SNRIs, triptans, tramadol, St. John’s wort). Seek urgent medical help if symptoms such as agitation, confusion, rapid heart rate, fever, muscle stiffness, or tremor occur.
- May increase risk of suicidal thoughts and behavior, especially in young adults at the start of treatment or after dose changes. Close monitoring by family and healthcare providers is essential.
- Use with caution in patients with liver or kidney impairment, seizure disorders, bipolar disorder (risk of mania), glaucoma, or bleeding disorders.
- May cause drowsiness, dizziness, or blurred vision. Avoid driving or operating machinery until you know how the medicine affects you.
- Alcohol consumption should be limited or avoided, as it may worsen side effects such as drowsiness and impaired judgment.
- Pregnancy and breastfeeding: Use only if clearly needed and prescribed by a doctor after assessing risks and benefits. Inform your doctor if you are pregnant, planning pregnancy, or breastfeeding.
- Not intended to diagnose, treat, cure, or prevent any disease without proper medical supervision.
- Keep out of reach of children.
Side Effects:
- Common side effects: nausea, vomiting, dry mouth, decreased appetite, diarrhea or constipation, dizziness, drowsiness, insomnia, sweating, tremor, headache, and sexual dysfunction (reduced libido, delayed ejaculation, difficulty achieving orgasm).
- Other possible effects: weight changes, nervousness, agitation, blurred vision, palpitations, mild increase in blood pressure, or rash.
- Serious side effects (seek immediate medical attention): signs of serotonin syndrome (agitation, confusion, fever, muscle rigidity, rapid heartbeat), severe allergic reactions (swelling of face, lips, tongue, or throat; difficulty breathing), seizures, severe mood changes, suicidal thoughts or behavior, unexplained bruising or bleeding, or severe skin reactions.
- Withdrawal symptoms may occur if treatment is stopped abruptly, including dizziness, sensory disturbances ("electric shock" sensations), sleep disturbances, anxiety, irritability, headache, and nausea. Always taper under medical supervision.
Storage Instructions:
Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.
Specifications:
- Product type: Prescription antidepressant medicine (SSRI).
- Form: Controlled-release film-coated tablet.
- Strength: 37.5 mg paroxetine per tablet.
- Pack size: 30 tablets per pack.
- Intended for adult use under medical supervision.
Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.

